Sixth of the "ASCO Direct™ China" webinar: Advancement of Targeted Therapy for Soft Tissue Sarcoma

About this event

Webinar Date:

  • China Time: Sunday, Aug 1st, 9:00 AM
  • US EST Time: Saturday, Jul 31th, 9:00 PM
  • US PST Time: Saturday, Jul 31th, 6:00 PM

Language: English, with Chinese simultaneous translation

Venue: Live Zoom Webinar

Webinar Agenda

Chairs:

US Co-Chairs:

  • Dr. Brian Van Tine, MD, PhD, Associate professor of medicine, Washington University School of Medicine

China Co-Chairs:

  • Dr. Wei Guo, Peking University People's Hospital

Presentations:

A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma

  • Dr. Brian Van Tine, MD, PhD, Associate professor of medicine, Washington University School of Medicine

TK216 for relapsed/refractory Ewing sarcoma: Interim phase 1/2 results

  • Dr. Noah Federman, MD, UCLA David Geffen School of Medicine

NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma

  • Dr. Suzanne George, MD, Harvard Medical School and Dana-Farber Cancer Institute

Efficacy and safety of anlotinib plus TQB2450 in patients with advanced soft tissue sarcoma: A multicenter, single armed, phase 1b trial

  • Dr. Jiayong Liu, Peking University Cancer Hospital

Panel Discussion

  • Dr. Brian Van Tine, MD, PhD, Associate professor of medicine, Washington University School of Medicine
  • Dr. Noah Federman, MD, UCLA David Geffen School of Medicine
  • Dr. Suzanne George, MD, Harvard Medical School and Dana-Farber Cancer Institute
  • Dr. Wei Guo, Peking University People's Hospital
  • Dr. Jiayong Liu, Peking University Cancer Hospital
  • Dr. Hong-Mei Zhang, Xijing Hospital
  • Dr. Xing Zhang, Sun Yat-sen University Cancer Center
  • Dr. Lu Xie, Peking University People’s Hospital
  • Dr. Jing Chen, Union Hospital, Tongji Medical College of HUST

Speakers and Panelists Bio

Dr. Brian Van Tine, MD, PhD, Associate professor of medicine, Washington University School of Medicine

I have set out on a lifelong mission to make an impact in the treatment of patients with sarcoma. I spent the first three years of my career developing a very large and robust trials-based sarcoma program at Washington University in St. Louis. This is now the largest program in the Midwest, and I have been the PI of over 40 clinical trials. I was awarded an early career development grant by the Sarcoma Alliance through Research and Collaboration.

EDUCATION

  • 1995 BS in Chemistry and BS in Biochemistry, University of Arizona, Tucson, AZ
  • 2003 PhD, University of Alabama, Birmingham, AL
  • 2005 MD, University of Alabama, Birmingham, AL
  • POST-GRADUATE TRAINING
  • 2005-2006 Internal Medicine Internship, Barnes-Jewish Hospital, Washington University, St. Louis, MO
  • 2006-2007 Internal Medicine Residency, Barnes-Jewish Hospital, Washington University, St. Louis, MO
  • 2007-2011 Oncology Fellowship, Barnes-Jewish Hospital, Washington University, St. Louis, MO
  • 2009-2010 Chief Fellow, Hematology and Oncology, Washington University, St. Louis, MO
  • ACADEMIC POSITIONS
  • 2011-2016 Assistant Professor of Medicine, Division of Medical Oncology, Washington University, St. Louis, MO
  • 2011-present Sarcoma Program Director, Division of Medical Oncology, Washington University, St. Louis, MO
  • 2016-present Associate Professor of Medicine, Division of Medical Oncology, Washington University, St. Louis, MO
  • APPOINTMENTS & COMMITTEES
  • 2011-2013 NCCN Panel of Soft Tissue Sarcoma
  • 2010-present Multidisciplinary Sarcoma Tumor Board, Washington University, Organizer and Moderator
  • 2013 ASCO Annual Meeting, Sarcoma Poster Discussion Session, Co-Chair
  • 2014 ASCO Annual Meeding, Novel Molecular and Metabolic Targets in Sarcome Education Session, Chair
  • 2014-present Alliance Developmental Therapeutics Committee, Correlative Vice Chair
  • 2014-present NRG Sarcoma Committee
  • 2015-present SARC Developmental Therapeutics Committee
  • 2015-present Siteman Steering Committee for Solid Tumors
  • 2015 AACR Basic Science of Sarcoma Meeting, Co-Chair
  • 2016 Siteman Cancer Center Genetics Program Committee
  • 2018-present Alliance Sarcoma Working Group, Co-Chair
  • BOARD CERTIFICATION
  • 2009-2019 Internal Medicine
  • 2014-2024 Medical Oncology
  • HONORS & AWARDS
  • 1997 Howard Hughes Medical Institute Summer Student Program
  • 1998 Participant in the Cold Spring Harbor Laboratory Summer Course: Advanced In Situ and Immunohistochemistry
  • 2001 Student Award for excellent presentation at the 19th International Papillomavirus Conference, Florianopolis, Brazil
  • 2001 UAB Comprehensive Cancer Center Poster Competition - Second Place
  • 2001 UAB Medical Student Research Day - First Place
  • 2001 Dean's Award for the Joint Health Sciences
  • 2003 Edward S. Reynolds Award for Investigative Pathology - National Research Day Forum, Galveston, TX
  • 2005-2011 Physician Scientist Training Program, Washington University in St. Louis
  • 2011 1st Place Poster "Loss of Taspase1 Abrogates HER2/neu Induced Breast Cancer", Washington University in St. Louis Breast Cancer Symposium
  • 2014 Presented the 2014 Rosenfeld Lecture for the Sarcoma Alliance for Research and Collaboration
  • PROFESSIONAL SOCIETIES
  • 2007-present American Society for Clinical Oncology
  • 2011-present Connective Tissue Oncology Society
  • 2011-present American Academy of Cancer Research
  • 2018-present European Society for Medical Oncology
  • EDITORIAL BOARDS
  • 2014-2019 Annals of Oncology
  • 2015-present Journal of Orthopaedic Research
  • 2018-2021 Journal of Clinical Oncology

Dr. Wei Guo, Peking University People's Hospital

Dr. Noah Federman, MD, UCLA David Geffen School of Medicine

Dr. Noah Federman is the Director of the Pediatric Bone and Soft Tissue Sarcoma Program at UCLA, part of the UCLA Sarcoma Program and UCLA's Jonsson Comprehensive Cancer Center. Dr. Federman specializes in treating children, adolescents and young adults with these aggressive cancers. He runs a incredibly comprehensive and & multidisciplinary program involving pediatric and medical oncologists, radiation oncologists, orthopedic oncology surgeons, musculoskeletal radiologists and pathologists, nuclear medicine specialists, physical therapists and prosthetic specialists. Dr. Federman also specializes in conducting clinical trials and leads an experienced clinical research team devoted to providing access to clinical trials for children with refractory, recurrent and metastatic bone and soft tissue cancers.

Dr. Suzanne George, MD, Harvard Medical School and Dana-Farber Cancer Institute

Suzanne George, MD, is the Director of Clinical Research for the Sarcoma Center at Dana-Farber Cancer Institute (DFCI) and Associate Professor of Medicine at Harvard Medical School.

She received her MD from University of Massachusetts Medical School after earning a degree in chemistry from Harvard College. She completed her internal medicine training at the University of North Carolina at Chapel Hill and Tufts in Boston, Massachusetts. She then completed a hematology/oncology fellowship at New England Medical Center/Tufts.

Dr. George has spent her career focused on clinical trials in sarcomas, with a focus on leiomyosarcoma and gastrointestinal stromal tumor (GIST). She has explored multiple novel therapeutics in this area and has been directly involved with the development of several compounds which have ultimately gained global regulatory approval as new standards of care in this field.

In addition to an established clinical investigator in this field, Dr. George is the Vice-Chair of the Alliance for Clinical Trials in Oncology, a large NCI funded oncology clinical trials research base, which is a part of the National Clinical Trials Network, She is a long time member of the soft tissue sarcoma panel of the National Comprehensive Cancer Network (NCCN), developing standard of care treatment guidelines for sarcoma and GIST. She is an active member of ASCO, ESMO and CTOS.

Dr. Jiayong Liu, Peking University Cancer Hospital

Dr. Hong-Mei Zhang, Xijing Hospital

Professor and Director of of Department of Oncology, Xijing Hospital

She is a practicing medical oncologist with research interest in tumor angiogenesis and immunology

Vice-chairmen of CMUP of China Anti-Cancer Association

Member of Sarcoma Committee of Chinese society of Clinical Oncology

Dr. Xing Zhang, Sun Yat-sen University Cancer Center

Dr. Xing Zhang is currently a professor and a chief physician of the department of Immunotherapy and Medical Oncology of Melanoma and Sarcoma in Sun Yat-sen University Cancer Center. She specializes in immunotherapy of solid tumor, molecular targeted drug therapy, medical treatment of bone and soft tissue sarcoma and melanoma. She is one of the Guangdong outstanding young medical talents and principle investigator of 4 National Natural Science Foundation projects. She has published dozens of SCI papers as the first author or correspondent author, including Oncogene, Mol Cancer, Br J Cancer, J ImmunoTherapy of Cancer, Clin Cancer Res, etc. She has also participated in the draft and development of 3 national medical treatment guidelines.

She served as group leader of chemoradiotherapy group of Sarcoma Professional Committee of China Anticancer Association, the chairman of Sarcoma Professional Committee of Guangdong anticancer association and the standing member of sarcoma Professional Committee of China Anticancer Association. She has other academic titles, including the member of target and individualized treatment special committee of Guangdong anticancer association, the vice chairman of Guangdong Cell Biology Association, the standing member of bone tumor branch of Guangdong Doctor Association, Guangdong Province Standing committee member of biotherapy special committee of anticancer association, the vice chairman of tumor support and rehabilitation treatment professional committee of Guangzhou anticancer association.

Research Interest(s): Immunotherapy of solid tumor and molecular targeted drug therapy. Medical treatment of bone and soft tissue sarcoma, melanoma .

Dr. Lu Xie, Peking University People’s Hospital

Medical Education

  • Peking University Medical College (Department of Clinical Medicine, Peking University), Beijing, China 2003-2011 DR. degree
  • Doctor of Clinical Medicine (8-year doctoral program)

Fellowship

  • Department of Musculoskeletal Oncology, Peking University People’s Hospital 2011-Present
  • Resident and Consultant of medical oncology for sarcoma
  • Department of Breast Cancer Center, Peking University People’s Hospital 2009-2011
  • Resident of Breast Cancer Center and other cancer centers for medical oncology

Dr. Jing Chen, Union Hospital, Tongji Medical College of HUST

Advancement of Targeted Therapy for Soft Tissue Sarcoma


ASCO Abstract #11505

A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma

ASCO Abstract #11500

TK216 for relapsed/refractory Ewing sarcoma: Interim phase 1/2 results

ASCO Abstract #11506

NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma

ASCO Abstract #11547

Efficacy and safety of anlotinib plus TQB2450 in patients with advanced soft tissue sarcoma: A multicenter, single armed, phase 1b trial


If you need to request a copy of the abstract, please send email to "webinars@eChinaHealth.com”.

Disclaimers: ASCO Licensing and eChinaHealth do not endorse any health care product, therapy, diagnostic test or device mentioned in this webinar.